Valuation: Compugen Ltd.

Market Cap 23Cr 20Cr 19Cr 17Cr 32Cr 2.18TCr 32Cr 218.41Cr 85Cr 1.09TCr 86Cr 84Cr 3.64TCr P/E 2026 *
-9.09x
P/E 2027 * -8.49x
Enterprise Value 23Cr 20Cr 19Cr 17Cr 32Cr 2.18TCr 32Cr 218.41Cr 85Cr 1.09TCr 86Cr 84Cr 3.64TCr EV / Sales 2026 *
21.3x
EV / Sales 2027 * 29.5x
Free-Float
97.9%
Yield 2026 *
-
Yield 2027 * -
1 day-3.60%
1 week+4.78%
Current month+2.55%
1 month+4.78%
3 months-15.44%
6 months+46.06%
Current year+57.52%
1 week 2.31
Extreme 2.31
2.5
1 month 2.17
Extreme 2.17
2.52
Current year 1.51
Extreme 1.51
3.24
1 year 1.3
Extreme 1.295
3.24
3 years 0.53
Extreme 0.53
3.24
5 years 0.51
Extreme 0.51
7.48
10 years 0.51
Extreme 0.51
19.9
Manager TitleAgeSince
Chief Executive Officer - 23/09/2025
Director of Finance/CFO 42 15/08/2024
Chief Operating Officer 49 01/01/2024
Director TitleAgeSince
Chairman 59 23/09/2025
Director/Board Member 59 11/06/2018
Director/Board Member 70 11/06/2018
Date Insider Type Main position Quantity % Market Cap.
29/07/26 Free

Chief Operating Officer

70,000 0.0740%
29/07/26 Free

Chairman

1,00,000 0.1058%
29/07/26 Free

Chief Financial Officer

45,500 0.0481%
Change 5-day change 1-year change 3-year change Capi.($)
-3.60%+4.78%+62.84%+117.12% 24Cr
+1.17%+1.09%+4.03%+15.74% 4.87TCr
-1.59%+2.12%+460.02%+573.56% 4.4TCr
-0.85%+7.95%+15.77%+80.09% 4.08TCr
-0.08%+3.91%+26.96%+9.86% 3.98TCr
0.00%+3.59%+20.51%+48.00% 3.27TCr
-3.61%-1.45% - - 1.68TCr
-2.52%-0.52%+24.35%+118.05% 1.67TCr
+0.72%+0.31%+4.94%+21.70% 1.39TCr
-1.09%+5.94%+81.46%+31.15% 1.36TCr
Average -1.14%+2.86%+77.88%+112.81% 2.67TCr
Weighted average by Cap. -0.60%+2.45%+97.50%+135.57%

Financials

2026 *2027 *
Net sales 1.07Cr 92.91L 87.1L 79.41L 1.49Cr 102.3Cr 1.52Cr 10Cr 4Cr 51Cr 4.02Cr 3.94Cr 170.82Cr 77.5L 67.18L 62.97L 57.42L 1.08Cr 74Cr 1.1Cr 7.41Cr 2.89Cr 37Cr 2.91Cr 2.85Cr 123.51Cr
Net income -2.51Cr -2.18Cr -2.04Cr -1.86Cr -3.5Cr -239.61Cr -3.56Cr -24Cr -9.38Cr -119.94Cr -9.43Cr -9.22Cr -400.12Cr -2.78Cr -2.41Cr -2.26Cr -2.06Cr -3.88Cr -265.42Cr -3.94Cr -27Cr -10Cr -132.86Cr -10Cr -10Cr -443.22Cr
Net Debt - -
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Employees
75
Date Price Change Volume
13/26/13 $2.410 -3.60% 2,80,003
12/26/12 $2.500 +4.17% 4,47,014
11/26/11 $2.400 +2.56% 2,97,200
10/26/10 $2.340 -2.90% 2,31,428
07/26/07 $2.410 +4.78% 2,76,177
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.410USD
Average target price
4.600USD
Spread / Average Target
+90.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CGEN Stock